Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.089x

Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.089x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-533.20K ≈ $-674.11K USD) by net assets (CHF5.96 Million ≈ $7.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Addex Therapeutics Ltd for a breakdown of total debt and financial obligations.

Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Sego Resources Inc V:SGZ	-0.015x
Industrial Minerals Ltd AU:IND	-0.077x
Farlim Group (Malaysia) Bhd KLSE:6041	-0.026x
Nakoda Group of Industries Limited NSE:NGIL	-0.031x
PharmaCyte Biotech Inc NASDAQ:PMCB	-0.027x
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc LSE:ATR	0.000x
SCC Holdings Bhd KLSE:0158	0.099x
Tri-Mode System M Bhd KLSE:0199	0.023x

Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2024)

The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Addex Therapeutics Ltd market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF9.67 Million ≈ $12.23 Million	CHF-5.37 Million ≈ $-6.79 Million	-0.556x	+92.04%
2023-12-31	CHF1.15 Million ≈ $1.45 Million	CHF-7.99 Million ≈ $-10.10 Million	-6.977x	-108.55%
2022-12-31	CHF4.91 Million ≈ $6.21 Million	CHF-16.44 Million ≈ $-20.78 Million	-3.346x	-285.22%
2021-12-31	CHF16.93 Million ≈ $21.41 Million	CHF-14.71 Million ≈ $-18.59 Million	-0.869x	-4.18%
2020-12-31	CHF14.61 Million ≈ $18.47 Million	CHF-12.18 Million ≈ $-15.40 Million	-0.834x	-124.41%
2019-12-31	CHF25.52 Million ≈ $32.27 Million	CHF-9.48 Million ≈ $-11.99 Million	-0.372x	-932.20%
2018-12-31	CHF39.24 Million ≈ $49.61 Million	CHF1.75 Million ≈ $2.21 Million	0.045x	+102.81%
2017-12-31	CHF1.34 Million ≈ $1.70 Million	CHF-2.13 Million ≈ $-2.70 Million	-1.590x	+87.10%
2016-12-31	CHF218.59K ≈ $276.36K	CHF-2.69 Million ≈ $-3.41 Million	-12.326x	-680.44%
2015-12-31	CHF1.66 Million ≈ $2.10 Million	CHF-2.63 Million ≈ $-3.32 Million	-1.579x	-105.86%
2014-12-31	CHF2.35 Million ≈ $2.97 Million	CHF-1.80 Million ≈ $-2.28 Million	-0.767x	+85.28%
2013-12-31	CHF3.03 Million ≈ $3.83 Million	CHF-15.78 Million ≈ $-19.95 Million	-5.214x	-188.38%
2012-12-31	CHF16.29 Million ≈ $20.60 Million	CHF-29.45 Million ≈ $-37.24 Million	-1.808x	-130.40%
2011-12-31	CHF33.84 Million ≈ $42.78 Million	CHF-26.55 Million ≈ $-33.57 Million	-0.785x	-61.27%
2010-12-31	CHF64.41 Million ≈ $81.44 Million	CHF-31.34 Million ≈ $-39.62 Million	-0.487x	+4.14%
2009-12-31	CHF77.58 Million ≈ $98.08 Million	CHF-39.38 Million ≈ $-49.78 Million	-0.508x	-239.45%
2008-12-31	CHF118.99 Million ≈ $150.44 Million	CHF-17.79 Million ≈ $-22.49 Million	-0.150x	+36.53%
2007-12-31	CHF140.11 Million ≈ $177.13 Million	CHF-33.00 Million ≈ $-41.73 Million	-0.236x	+49.08%
2006-12-31	CHF42.28 Million ≈ $53.45 Million	CHF-19.56 Million ≈ $-24.73 Million	-0.463x	--

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology

Market Cap

$9.27 Million

CHF7.33 Million CHF

Market Cap Rank

#27648 Global

#209 in Switzerland

Share Price

CHF0.05

Change (1 day)

-0.40%

52-Week Range

CHF0.04 - CHF0.07

All Time High

CHF3.90